Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients

Table 2

Biochemical and BMD characteristics of the study population.

	Olanzapine-treated group ()	First episode drug-naïve group ()	Healthy control ()	^#	Multicomparison
TG (mmol/L)				<0.001
CHOL (mmol/L)				<0.001	, H
HDL (mmol/L)				<0.001	O,
LDL (mmol/L)				<0.001
FBG (mmol/L)				<0.001	, H
Insulin (μU/mL)				<0.001	, H
BMD, radius+ulna (g/cm^2)
1/3				0.275	—
MID				<0.001	O,
UD				<0.001	O,
TOTAL					O,
BMD, lumbar (g/cm^2)
L1				0.023
L2				0.018
L3				0.005	O,
L4				<0.001
L1-4				0.002	, H
BMD, left hip (g/cm^2)
NECK				0.003	O,
TROCH				<0.001	O,
WARD				0.066	—
T-HIP				0.017

^#Comparison of biochemical and BMD characteristics among the olanzapine-treated, first episode drug-naïve, and healthy control groups.